CPLX2, complexin 2, 10814

N. diseases: 22; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 GeneticVariation disease BEFREE Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. 20819981 2010
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 GeneticVariation disease BEFREE Since increased working memory-related neural activity in individuals with or at risk for schizophrenia has been interpreted as 'neural inefficiency,' these findings suggest that certain variants of CPLX2 may contribute to impaired brain function in schizophrenia, possibly combined with other deleterious genetic variants, adverse environmental events, or developmental insults. 25297695 2015
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.110 GeneticVariation disease BEFREE We also detected rare inherited CNVs in 19 of 248 (7.7%) ADHD probands, which were absent in 2357 controls and which either overlapped previously implicated ADHD loci (for example, DRD5 and 15q13 microduplication) or identified new candidate susceptibility genes (ASTN2, CPLX2, ZBBX, and PTPRN2). 21832240 2011
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.110 GeneticVariation disease GWASCAT Genome-wide association study of inattention and hyperactivity-impulsivity measured as quantitative traits. 23527680 2013
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.100 GeneticVariation disease GWASDB Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. 21211798 2011
CUI: C1832423
Disease: Cataract, Age-Related Nuclear
Cataract, Age-Related Nuclear 		0.100 GeneticVariation phenotype GWASCAT Meta-analysis of genome-wide association studies in multiethnic Asians identifies two loci for age-related nuclear cataract. 24951543 2014
CUI: C0221505
Disease: Lesion of brain
Lesion of brain 		0.010 GeneticVariation group BEFREE Correspondingly, in Cplx2 -null mutant mice, prominent cognitive loss of function was obtained only in combination with a minor brain lesion applied during puberty, modeling a clinically relevant environmental risk ("second hit") for schizophrenia. 20819981 2010
CUI: C0338656
Disease: Impaired cognition
Impaired cognition 		0.010 GeneticVariation disease BEFREE Previous studies found common variants in the complexin2 (CPLX2) gene to be highly associated with cognitive dysfunction in schizophrenia patients. 25297695 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE For both mRNA and protein, the complexin II/complexin I ratio was lower in schizophrenia, confirming the relatively greater loss of the excitatory marker. 9853440 1998
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE We measured the expression of three synaptic proteins (synaptophysin, complexin I and complexin II) in the cerebellar cortex of 16 subjects with schizophrenia and 16 controls using in situ hybridisation histochemistry and immunoautoradiography. 11483314 2001
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE In this in situ hybridization histochemistry (ISHH) study, we examined four informative synaptic protein transcripts: vesicular glutamate transporter (VGLUT) 1, VGLUT2, complexin I, and complexin II, in dorsolateral prefrontal cortex (DPFC), superior temporal cortex (STC), and hippocampal formation, in 13 subjects with schizophrenia and 18 controls. 15653259 2005
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE We conducted a genetic association analysis between complexin genes (CPLX1 and CPLX2) and schizophrenia in Japanese patients (377 cases and 341 controls). 16442780 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease BEFREE No significant changes in complexin 1, VGAT, complexin 2, VGluT1, dysbindin, NAV2, or VAMP1 mRNA expression were found; however, expression of mRNAs associated with plasticity/cytoskeletal modification (GAP43 and NAV1) was reduced in schizophrenia. 21145444 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease LHGDN In schizophrenia, VGLUT1 mRNA was decreased in hippocampal formation and DPFC, complexin II mRNA was reduced in DPFC and STC, and complexin I mRNA decreased in STC. 15653259 2005
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease CTD_human In schizophrenia, synaptophysin mRNA was decreased, as was complexin II and its mRNA. 11483314 2001
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.580 Biomarker disease MGD As dysfunction in synaptic transmission plays a key role in schizophrenia, and complexin2 (CPLX2) gene expression is reduced in hippocampus of schizophrenic patients, we developed a mouse model with Cplx2 null mutation as genetic risk factor and a mild parietal neurotrauma, applied during puberty, as environmental 'second hit'. 20412316 2010
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.310 Biomarker disease PSYGENET Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. 20584925 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.310 Biomarker disease PSYGENET Our data strongly support the idea that complexin 2 is a key player in normal neurological function, and that downregulation of complexin 2 could lead to changes in neurotransmitter release sufficient to cause significant behavioural abnormalities such as depression. 20584925 2010
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0005587
Disease: Depression, Bipolar
Depression, Bipolar 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0024713
Disease: Manic Disorder
Manic Disorder 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0033958
Disease: Psychosis, Brief Reactive
Psychosis, Brief Reactive 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0033975
Disease: Psychotic Disorders
Psychotic Disorders 		0.300 Biomarker group CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004
CUI: C0036337
Disease: Schizoaffective Disorder
Schizoaffective Disorder 		0.300 Biomarker disease CTD_human Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. 14708030 2004